You’re reading the web version of STAT’s popup newsletter, AACR in 30 seconds, your guide to what’s happening at the American Association of Cancer Researchers’ annual meeting. This is the last edition of our pop-up newsletter.
We hope you’ve learned as much as we have. If you’re not already a STAT+ subscriber, consider it!
There’s currently a  60% off promotion  on annual subscriptions. In the meantime, thanks for joining us.
Overcoming resistance and RevMed’s next drug? In case you missed it, Revolution Medicines’ sessions yesterday were jam-packed with conference attendees.
While most of the media coverage focused on the daraxonrasib in frontline pancreatic cancer data, the company also revealed some activity in a new compound, RM-055. CEO Mark Goldsmith described it as being part of a new class of “catalytic inhibitors,” since it can slice off a phosphate from GTP-RAS, or the “on” form of RAS, and turn the protein off.
You are reading a brief conference dispatch from STAT’s AACR pop-up newsletter summarizing highlights presented at the American Association for Cancer Research annual meeting.
The report signals this is the final issue of that pop-up series and references a promotional subscription offer; those operational details are peripheral to the scientific content.
Revolution Medicines drew strong attendance for its presentations.
Media attention centered on daraxonrasib data in first‑line pancreatic cancer, but the company also disclosed findings on a distinct investigational agent, RM‑055.
RM‑055 was described by the company’s CEO as belonging to a purportedly new category of “catalytic inhibitors.” The molecule is said to catalytically remove a phosphate from GTP‑bound RAS (the active state), thereby converting the protein to its inactive form.
The company framed this mechanism as enabling a single molecule to inactivate multiple RAS proteins.
Presenters contextualized RM‑055 in terms of an established resistance mechanism to RAS pathway inhibitors: tumors can increase mutant RAS abundance, which may outcompete conventional inhibitors.
A catalytic modality that can inactivate multiple RAS molecules was presented as a potential strategy to address resistance arising from mutant RAS amplification.
The newsletter notes public interest and company claims but does not provide trial design details, quantitative efficacy or safety data, patient population characteristics, or stages of development for RM‑055.
No independent corroboration or peer‑reviewed evidence is cited in the item.